Hims & Hers

Hims & Hers launched Biotin + Minoxidil Gummy (June 2025), its first prescription gummy product, targeting wellness-focused consumers with CPG-style packaging and form factors. The product is reporting high adherence rates.

Leadership read: Hims & Hers's launch shifts talent demand before revenue catches up. In Digital Health, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether Hims & Hers backs it with senior go-to-market hires across Americas — that separates a platform move from a one-off.

curated · 2026-08-05 · context →

Hims & Hers moved media account from Tinuiti to PMG following competitive review

Leadership read: Hims & Hers entered 2025 spending $237 million on measured media and exited it having cut that figure to $198 million, a 17% reduction that reframes this review. The shift from Tinuiti to PMG is not simply a competitive win for one independent; it marks a deliberate reset of how the company allocates media at reduced scale. Tinuiti built the Super Bowl relationship. PMG brings a stronger orientation toward full-funnel performance and premium digital environments. The operational commitment is to do more with less, which puts media efficiency and attribution rigor at the center of the new agency relationship from day one. This is one of twelve partnership signals we have tracked in the last 90 days across consumer health and direct-to-consumer media categories, though the related set here is thin on direct comparables. The cleaner parallel lives inside the broader agency review wave: IBM ending a 32-year Ogilvy relationship, Microsoft Copilot moving to Droga5, Levi's dissolving its AOR model entirely. The through-line is brands reorienting agency relationships around performance accountability and creative precision as total spend compresses. Companies at Hims & Hers' stage of DTC maturity, high media intensity, margin pressure, regulatory scrutiny on health claims, face concentrated demand for commercial leadership capable of operating at the intersection of performance marketing, brand stewardship, and compliant messaging. The market is moving toward operators who can govern agency ecosystems rather than simply manage single-agency mandates.

curated · 2026-07-06 · context →

Hims & Hers expanded its benefits program by adding eight major fitness and wellness partners (Pvolve, MyFitnessPal, Ladder, iFIT, Natural Cycles, HelloFresh, Factor, Flo Health, Dexcom) to create a holistic health ecosystem supporting GLP-1 treatment and preventative wellness.

Leadership read: The eight-partner expansion commits Hims & Hers to a fundamentally different operational architecture. Until now, its model was a clinical delivery platform, prescriptions, treatment plans, physician access. Adding nutrition, fitness tracking, metabolic monitoring, and women's cycle data from nine external platforms means the company now owns the member relationship across behavioral and lifestyle dimensions it previously did not touch. That creates real data-integration obligations: subscriber journeys now span glucose biosensors, meal kits, strength programming, and hormonal tracking simultaneously, all of which must cohere into a product experience that retains members and, credibly, drives outcomes that justify the GLP-1 positioning. The related signals set is thin on direct health-ecosystem comparables, most of the 12 signals tracked in this window are geographically and sectorally remote (defence, export programs, esports, EDA). The honest read is that this sits in a relatively uncrowded pattern within telehealth specifically: consumer health companies building bundled, non-clinical wraparound ecosystems to defend GLP-1 subscriber economics. The closest structural comparables are Amazon Clinic's benefits bundling and Noom's shift toward integrated coaching stacks, though neither has assembled a partner set of this breadth in a single program announcement. Companies reaching this stage of partner-ecosystem assembly in consumer health face consistent demand for leadership across partnerships and commercial structuring, data product engineering at the member-data integration layer, and outcomes measurement capable of validating retention claims against clinical benchmarks. The market is moving toward operators who can hold commercial and clinical accountability in the same function, a hybrid that remains genuinely scarce in the telehealth corridor.

curated · 2026-05-28 · context →

Hims & Hers acquired their largest international competitor Eucalyptus for $1.5B, indicating major expansion and integration needs

Leadership read: The acquisition commits Hims & Hers to an integration problem it has never run before. Operating a direct-to-consumer telehealth platform in a single regulatory environment is a contained execution challenge; absorbing a $1.5B competitor built on a different market's regulatory architecture, prescription frameworks, and clinical supply chains is not. Eucalyptus was purpose-built for Australia and the UK, markets with distinct pharmacy licensing, prescribing rules, and data-sovereignty requirements. Hims & Hers has now taken on simultaneous obligations in market-entry execution, technology integration, and clinical operations standardization across jurisdictions where it has no prior operating history. This is one of twelve M&A signals we have tracked across sectors in the last 90 days, though the Hims-Eucalyptus deal is the only one in consumer telehealth at cross-border scale. The broader set. Couche-Tard's $8.7B Żabka acquisition, IG Group's $1.3B Underdog deal, reflects a pattern of category leaders using M&A to compress geographic or product expansion timelines rather than building organically. The consistent shape across these deals: speed of strategic commitment outpaces depth of integration readiness. Companies reaching this stage of cross-border platform consolidation in regulated consumer health face concentrated demand for leadership in international regulatory operations, clinical governance across multiple licensing regimes, cross-border product and engineering integration, and commercial leaders who understand market-specific GTM rather than platform-wide performance marketing assumptions.

curated · 2026-04-04 · context →